Sanofi Found by UK Regulator in Breach of Pharmaceutical Industry Code

MT Newswires Live02-02 21:31

Sanofi (SNY) has been found by UK's Prescription Medicines Code of Practice Authority in breach of the Association of the British Pharmaceutical Industry code of practice for allegedly making "misleading" claims about its Beyfortus drug and disparaging Pfizer's (PFE) rival vaccine, the regulator said Monday.

Sanofi's action "brought discredit upon and reduced confidence" in the pharmaceutical industry, according to the regulator.

The case stemmed from Pfizer's complaint about an article in a UK Sunday newspaper that contained comments by a Sanofi executive claiming Beyfortus is superior.

Beyfortus is a monoclonal antibody for the prevention of respiratory syncytial virus, or RSV, in infants. Pfizer's Abrysvo vaccine is being used in the UK's maternal vaccination program to help protect newborns and infants from RSV, the regulator said in its case report.

Sanofi did not immediately reply to a request for comment from MT Newswires.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608864612?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-02 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608864612","market":"sg","top_or_hot":-1,"title":"Sanofi Found by UK Regulator in Breach of Pharmaceutical Industry Code","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (SNY) has been found by UK's Prescription Medicines Code of Practice Authority in breach of the Association of the British Pharmaceutical Industry code of practice for allegedly making \"misleading\" claims about its Beyfortus drug and disparaging Pfizer's (PFE) rival vaccine, the regulator said Monday.</p><p><a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a>'s action \"brought discredit upon and reduced confidence\" in the pharmaceutical industry, according to the regulator.</p><p>The case stemmed from Pfizer's complaint about an article in a UK Sunday newspaper that contained comments by a Sanofi executive claiming Beyfortus is superior.</p><p>Beyfortus is a monoclonal antibody for the prevention of respiratory syncytial virus, or RSV, in infants. Pfizer's Abrysvo vaccine is being used in the UK's maternal vaccination program to help protect newborns and infants from RSV, the regulator said in its case report.</p><p>Sanofi did not immediately reply to a request for comment from MT Newswires.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Found by UK Regulator in Breach of Pharmaceutical Industry Code</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Found by UK Regulator in Breach of Pharmaceutical Industry Code\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-02 21:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (SNY) has been found by UK's Prescription Medicines Code of Practice Authority in breach of the Association of the British Pharmaceutical Industry code of practice for allegedly making \"misleading\" claims about its Beyfortus drug and disparaging Pfizer's (PFE) rival vaccine, the regulator said Monday.</p><p><a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a>'s action \"brought discredit upon and reduced confidence\" in the pharmaceutical industry, according to the regulator.</p><p>The case stemmed from Pfizer's complaint about an article in a UK Sunday newspaper that contained comments by a Sanofi executive claiming Beyfortus is superior.</p><p>Beyfortus is a monoclonal antibody for the prevention of respiratory syncytial virus, or RSV, in infants. Pfizer's Abrysvo vaccine is being used in the UK's maternal vaccination program to help protect newborns and infants from RSV, the regulator said in its case report.</p><p>Sanofi did not immediately reply to a request for comment from MT Newswires.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B19Z3B42.SGD","symbol_name":"Legg Mason ClearBridge - Value A Acc SGD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2608864612","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608864612","pubTimestamp":1770039097,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sanofi  has been found by UK's Prescription Medicines Code of Practice Authority in breach of the Association of the British Pharmaceutical Industry code of practice for allegedly making \"misleading\" claims about its Beyfortus drug and disparaging Pfizer's  rival vaccine, the regulator said Monday.Sanofi's action \"brought discredit upon and reduced confidence\" in the pharmaceutical industry, according to the regulator.The case stemmed from Pfizer's complaint about an article in a UK Sunday newspaper that contained comments by a Sanofi executive claiming Beyfortus is superior.Beyfortus is a monoclonal antibody for the prevention of respiratory syncytial virus, or RSV, in infants. Pfizer's Abrysvo vaccine is being used in the UK's maternal vaccination program to help protect newborns and infants from RSV, the regulator said in its case report.Sanofi did not immediately reply to a request for comment from MT Newswires.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","BK7095":"多种金属与采矿","BK4534":"瑞士信贷持仓","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","BK4592":"伊斯兰概念","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4550":"红杉资本持仓","BK4588":"碎股","BK4568":"美国抗疫概念","SG9999001176.USD":"United Global Healthcare Acc USD","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4007":"制药","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","SG9999002232.USD":"Allianz Global High Payout USD","BK4581":"高盛持仓","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","SNY":"赛诺菲安万特","BK4599":"减肥药","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4585":"ETF&股票定投概念"},"translate_title":"英国监管机构发现赛诺菲违反制药行业法规","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNY":1.95},"content_text":"Sanofi (SNY) has been found by UK's Prescription Medicines Code of Practice Authority in breach of the Association of the British Pharmaceutical Industry code of practice for allegedly making \"misleading\" claims about its Beyfortus drug and disparaging Pfizer's (PFE) rival vaccine, the regulator said Monday.Sanofi's action \"brought discredit upon and reduced confidence\" in the pharmaceutical industry, according to the regulator.The case stemmed from Pfizer's complaint about an article in a UK Sunday newspaper that contained comments by a Sanofi executive claiming Beyfortus is superior.Beyfortus is a monoclonal antibody for the prevention of respiratory syncytial virus, or RSV, in infants. Pfizer's Abrysvo vaccine is being used in the UK's maternal vaccination program to help protect newborns and infants from RSV, the regulator said in its case report.Sanofi did not immediately reply to a request for comment from MT Newswires.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608864612","isCrawlerRequest":true}